Mycophenolate Mofetil Treats Immune Thrombocytopenia
Fewer treatment failures and greater response, but poorer quality of life seen when added to a glucocorticoid for first - line treatment (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 2, 2021 Category: Cancer & Oncology Tags: Oncology, Pathology, Pharmacy, Journal, Source Type: news
Mycophenolate Mofetil Treats Immune Thrombocytopenia
THURSDAY, Sept. 2, 2021 -- For adults with immune thrombocytopenia, the addition of mycophenolate mofetil to a glucocorticoid for first-line treatment is associated with fewer treatment failures and higher response rates than glucocorticoid-only... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 2, 2021 Category: Pharmaceuticals Source Type: news
What are Some of the Complications of Short Bowel Syndrome?
Discussion
Necrotizing enterocolitis (NEC) is one of the most common gastrointestinal emergencies in neonates. Mortality rates are from 0-45% depending on infant weight and gestation with more premature and smaller infants having greater mortality. NEC usually occurs in premature infants but it also occurs in term infants. The etiology is unknown but is probably multifactorial with ischemia and/or reperfusion playing some role. There are ‘outbreaks’ of NEC but no causative organism has been identified. Regardless of the originating cause, inflammation of the intestine and release of inflammatory mediators causes variou...
Source: PediatricEducation.org - August 30, 2021 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news
Features of Vaccine-Induced Thrombotic Syndrome Studied
THURSDAY, Aug. 12, 2021 -- Mortality seen in association with vaccine-induced immune thrombocytopenia and thrombosis (VITT) after the first dose of the ChAdOx1 nCoV-19 vaccine (Oxford-AstraZeneca) is increased for those with cerebral venous sinus... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 12, 2021 Category: Pharmaceuticals Source Type: news
Coronavirus disease 2019 (COVID-19) Updates, BMJ Best Practice
1. NICE publishes new guidance on vaccine-induced immune thrombocytopenia and thrombosis. 2. FDA authorises casirivimab/imdevimab for prevention of COVID-19.
3. EMA warns of Guillain-Barre syndrome with Janssen COVID-19 vaccine.
4. EMA authorises use of Moderna COVID-19 vaccine in young people aged 12 to 17 years. 5. CDC warns that vaccinated people with breakthrough infections can spread the Delta variant. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - August 10, 2021 Category: Consumer Health News Source Type: news
European PRAC updated safety issues with Janssen COVID-19 Vaccine, EMA
PRAC has recommended including immune thrombocytopenia, dizziness and tinnitus as adverse reactions, and to re-classify ' thrombocytopenia ' , currently an important potential risk, as an important identified risk. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - August 10, 2021 Category: Consumer Health News Source Type: news
Pfizer vaccine: Rates of deep vein thrombosis and thrombocytopenia after vaccine increase
AS MANY as 32 million people across the UK will be offered the COVID-19 vaccine in a bid to boost immunity ahead of winter. Although the Pfizer vaccine has proven highly effective at preventing serious illness from COVID-19, a recent study has suggested the jab could carry the rare risk of thrombocytopenia and deep vein thrombosis . (Source: Daily Express - Health)
Source: Daily Express - Health - August 7, 2021 Category: Consumer Health News Source Type: news
Johnson & Johnson ’s COVID-19 Shot Works Well Against Delta Variant, Study Finds
Johnson & Johnson’s COVID-19 vaccine helps prevent severe disease among those infected with the Delta variant, according to a trial involving almost 480,000 health workers in South Africa.
The study, known as Sisonke, provides the first large-scale evidence that the J&J vaccine works against this dominant variant, according to trial co-lead Glenda Gray. It’s probably more protective against Delta than it was with the earlier beta strain, she said in a presentation Friday.
The single-dose shot was 71% effective against hospitalization and as much as 96% effective against death, she said. It also demonstr...
Source: TIME: Health - August 6, 2021 Category: Consumer Health News Authors: Janice Kew and Antony Sguazzin / Bloomberg Tags: Uncategorized COVID-19 Source Type: news
NICE guideline - blood clotting condition associated with COVID-19 vaccination
NICE has published a new rapid COVID-19 guideline to help healthcare staff identify and treat patients who develop the rare syndrome vaccine-induced immune thrombocytopenia and thrombosis (VITT) after receiving COVID-19 vaccinations. (Source: NHS Networks)
Source: NHS Networks - August 2, 2021 Category: UK Health Source Type: news
COVID-19 rapid guideline: vaccine-induced immune thrombocytopenia and thrombosis (VITT) [NG200], NICE (published 29th July 2021)
This guideline covers vaccine-induced immune thrombocytopenia and thrombosis (VITT), a syndrome which has been reported in rare cases after COVID-19 vaccination. VITT may also be called vaccine-induced prothrombotic immune thrombocytopenia (VIPIT) or thrombotic thrombocytopenic syndrome (TTS). Because VITT is a new condition, there is limited evidence available to inform clinical management, identification and management of the condition is evolving quickly as the case definition becomes clearer. This guideline was produced to support clinicians to diagnose and manage this newly recognised syndrome. (Source: Current Awaren...
Source: Current Awareness Service for Health (CASH) - July 29, 2021 Category: Consumer Health News Source Type: news
Vaxzevria and mRNA COVID-19 vaccines showed similar and favourable safety profiles in a population-based cohort study of over a million people
In a large real-world study, data published as a pre-print on The Lancet server from over one million individuals assessed the incidence rates of blood clotting disorders of thromboembolism and thrombocytopenia, including the very rare thrombosis with thrombocytopenia (TTS) following vaccination with an mRNA vaccine or Vaxzevria, and compared them with expected rates in a general population and in people with COVID-19. (Source: World Pharma News)
Source: World Pharma News - July 28, 2021 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news
Rare blood clot cases not higher after AstraZeneca second dose: Study
The data found that the estimated rate of thrombosis with thrombocytopenia syndrome (TTS) after the second dose of the vaccine, Vaxzevria, was 2.3 per million in those inoculated, comparable to the typical rate seen in those who have not been vaccinated, AstraZeneca said. (Source: The Economic Times)
Source: The Economic Times - July 28, 2021 Category: Consumer Health News Source Type: news
Coronavirus vaccine - weekly summary of Yellow Card reporting (22 July), MHRA (updated 22nd July 2021)
This report (updated weekly) is based on analysis of data up to 14 July. It discusses overall safety and comments on specific reports, including thromboembolic events with thrombocytopenia, capillary leak syndrome, menstrual disorders, myocarditis/pericarditis, and others. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - July 26, 2021 Category: Consumer Health News Source Type: news
Organs From Deceased Recipients of AstraZeneca COVID-19 Vaccine May Pose Problems Organs From Deceased Recipients of AstraZeneca COVID-19 Vaccine May Pose Problems
Organs from deceased donors who had received AstraZeneca ' s vaccine against SARS-CoV-2 may possibly prompt vaccine-induced thrombosis and thrombocytopenia in recipients, according to a new study.Reuters Health Information (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - July 24, 2021 Category: Transplant Surgery Tags: Infectious Diseases News Source Type: news
Treatment for people suffering from Covid vaccine-related blood clots found
The researchers at the McMaster University recommend a combination of anti-clotting drugs and high doses of intravenous immunoglobulin to combat vaccine-induced immune thrombotic thrombocytopenia (VITT). (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - July 1, 2021 Category: Pharmaceuticals Source Type: news
